Zuma

d-Matrix builds purpose-built silicon for generative AI inference using digital in-memory compute architecture. Founded in 2019, the company approaches inference workloads from first principles rather than adapting GPU architectures, targeting the core bottleneck of data movement between memory and processors. Their Corsair platform addresses latency, throughput, and energy constraints specific to running LLMs and generative models at production scale. The technical stack spans silicon design (SystemVerilog, UVM), systems engineering (PCIe, RISC-V, FPGA), and software infrastructure (MLIR, PyTorch, TensorFlow, ONNX Runtime, TensorRT). With over 200 engineers, the company operates at the intersection of hardware architecture, compiler development, and inference runtime optimization. The focus is making generative AI commercially viable beyond hyperscale deployments - reducing both operational cost and energy consumption per token through architectural changes rather than incremental improvements. d-Matrix's approach centers on co-designing compute, memory hierarchy, and software to eliminate traditional bottlenecks in inference workloads. The team works on problems ranging from physical silicon verification through compiler transformations to inference serving infrastructure. Their claims around ultra-low latency and high throughput depend on in-memory compute reducing off-chip memory access patterns that dominate inference cost profiles in conventional architectures.

Xaira Therapeutics is an integrated biotechnology company founded in 2023 that combines AI model development, large-scale biological data generation, and therapeutic product development under one organization. Built on protein design research from the University of Washington's Institute for Protein Design and Dr. David Baker's work, the company raised over $1 billion before emerging from stealth in 2024. Co-founded and incubated by ARCH Venture Partners and Foresite Labs, Xaira operates across three locations: South San Francisco, Seattle, and London. The technical infrastructure spans protein design, predictive patient stratification, and drug discovery systems. The stack includes Python, C++, PyTorch, and Jax for modeling, with distributed training approaches using DDP and FSDP. Experimental infrastructure includes Cytiva AKTA and Agilent HPLC systems for protein characterization and purification workflows. The company's approach integrates computational predictions with wet-lab data generation at scale, attempting to shift drug discovery from empirical methods toward engineered precision. Technical domains span AI model development for biological systems, protein engineering, therapeutic design, and patient selection algorithms. The organization is led by David Baker and Marc Tessier-Lavigne, combining academic protein design expertise with pharmaceutical development experience. The integration of model training, experimental validation loops, and therapeutic development pipeline represents a vertically integrated structure where data generation, model iteration, and product development occur within the same organization.

Chai Discovery builds frontier AI foundation models to predict and reprogram biochemical molecular interactions, transforming drug discovery from empirical screening of billions of candidate sequences into deterministic computational design. The company's platform achieves over 85% success rates in designing molecules that meet drug-like properties - a fundamental shift from traditional approaches that require years of wet-lab iteration and billions in capital. Founded by researchers who co-invented protein language modeling and built state-of-the-art folding algorithms, Chai Discovery has shipped Chai-1 and Chai-2, breakthrough models for computational molecular design now deployed in production pharmaceutical workflows. The technical stack spans protein language modeling, protein folding algorithms, computational antibody design, and molecular interaction prediction. The platform handles previously undruggable targets, including GPCR agonist design with minimal experimental screening - a capability that addresses targets accounting for roughly 30% of marketed drugs but historically requiring extensive trial-and-error optimization. Design precision operates at atomic resolution, enabling drug-like antibody engineering with explicit control over molecular properties rather than stochastic library screening. Chai Discovery is backed by OpenAI, Thrive Capital, and General Catalyst, and maintains active partnerships with pharmaceutical companies including Eli Lilly. The company operates from the US under CEO Joshua Meier, deploying models that compress multi-year discovery timelines into computational workflows. For engineers, the inference challenge involves running large-scale protein structure prediction and molecular design models in production environments where latency and throughput directly gate pharmaceutical R&D cycles, with evaluation rigor defined by experimental validation rates rather than benchmark metrics.

OpenEvidence operates a HIPAA-compliant medical information platform that handles over 100 million AI-powered clinical consultations from U.S. doctors and frontline clinicians. The system functions as a natural language search and retrieval layer over medical literature, synthesizing evidence from trusted sources to deliver point-of-care clinical decision support. With more than 40% of U.S. physicians logging in daily, the platform addresses a core bottleneck in clinical workflows: the exponential growth of medical knowledge against fixed physician time budgets. The system surfaces relevant evidence in seconds rather than the hours traditional literature review requires. The technical architecture supports evidence synthesis across landmark medical literature, aggregating content through clinical partnerships while maintaining compliance constraints required for healthcare settings. The platform serves as a knowledge management system that operates across practice environments - from academic medical centers to rural clinics - suggesting infrastructure designed for variable network conditions and diverse deployment contexts. Free access for verified U.S. healthcare professionals indicates a distribution model optimized for maximum clinician adoption rather than per-seat pricing common in enterprise healthcare software. Core technical domains span clinical decision support, AI copilot functionality for clinicians, and content aggregation from medical literature sources. The system's reliability requirements are elevated given its role in clinical decision pathways affecting patient outcomes, demanding careful evaluation of failure modes where incorrect or incomplete evidence synthesis could influence treatment decisions.

Bioptimus builds foundation models for biology and biomedical applications, with H-Optimus as its flagship model for digital pathology. H-Optimus ranks #1 among 22 evaluated pathology foundation models and was trained on 2 billion images contributed by over 4,000 clinical practices. The company targets deployment across drug discovery, clinical trial analytics, and clinical decision support, with approximately 100 scientific publications annually leveraging their models and a projection toward 1 million total downloads across their model family. The technical challenge centers on multiscale biological data integration - mapping representations from molecular to organism level while maintaining utility across diverse downstream tasks. Model evaluation in this domain involves trade-offs between pretraining data volume, task transfer performance, and domain-specific fine-tuning requirements. Digital pathology specifically presents bottlenecks in gigapixel image processing, label noise from clinical annotation workflows, and distribution shift between training cohorts and deployment sites. Bioptimus has raised $76 million and operates from France. The company's stated goal is producing a universal foundation model for biology, positioning their work at the intersection of large-scale self-supervised learning, biological domain knowledge encoding, and production deployment in regulated healthcare environments.

Clarifai operates a full-stack AI platform spanning data preparation, model training, deployment, and monitoring across computer vision, NLP, and audio domains. The platform serves over 400,000 users across 170+ countries, delivering billions of predictions with access to more than 1 million models. Founded in 2013 by Matthew Zeiler after winning top five placements at ImageNet 2013, the company has raised $100 million in funding from Menlo Ventures, Union Square Ventures, NVIDIA, Google Ventures, and Qualcomm. Customers include Amazon, Siemens, NVIDIA, Canva, Vimeo, and OpenTable. The inference architecture supports orchestrated compute across AWS, GCP, and Azure, with edge deployment through Local Runners for on-premises and edge scenarios. The platform integrates PyTorch, TensorFlow, JAX, Nvidia Triton, and ONNX, with reported performance of 544 tokens per second on GPT-OSS-120B. Technical focus areas include image classification, video analysis, multimodal processing, and MLOps workflows. The stack runs on Python and Golang, with Kubeflow for pipeline orchestration. The company positions itself as enterprise- and developer-focused, addressing the full AI lifecycle from unstructured data ingestion through production monitoring. Forrester recognized Clarifai as a leader in its Computer Vision report. The platform's scope spans model training, inference orchestration, and operational deployment across cloud and edge environments, serving use cases in e-commerce, manufacturing, semiconductors, creative software, media, and hospitality verticals.